Calithera Biosciences, Inc.

Form 3 October 01, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB APPROVAL** FORM 3 Washington, D.C. 20549 OMB 3235-0104 Number: January 31, **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** Expires: 2005 **SECURITIES** Estimated average burden hours per Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... 0.5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 (Print or Type Responses) 1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Calithera Biosciences, Inc. [CALA] Delphi Management Partners (Month/Day/Year) 10/01/2014 VIII, L.L.C. (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O DELPHI (Check all applicable) VENTURES., 3000 SAND HILL ROAD, BLDG. 1, SUITE _X_ 10% Owner Director 135 Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person MENLO PARK. CAÂ 94025 _X_ Form filed by More than One Reporting Person (City) (State) (Zip) **Table I - Non-Derivative Securities Beneficially Owned** 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities 3. Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	(1)	(1)	Common Stock	6,808	\$ <u>(1)</u>	Ι	Delphi Ventures VIII, L.P. (2)
Series A Preferred Stock	(1)	(1)	Common Stock	66	\$ <u>(1)</u>	Ι	Delphi BioInvestments VIII, L.P. <u>(3)</u>
Series B Preferred Stock	(1)	(1)	Common Stock	415,128	\$ <u>(1)</u>	Ι	Delphi Ventures VIII, L.P. (2)
Series B Preferred Stock	(1)	(1)	Common Stock	4,053	\$ <u>(1)</u>	Ι	Delphi BioInvestments VIII, L.P. <u>(3)</u>
Series C Preferred Stock	(1)	(1)	Common Stock	740,312	\$ <u>(1)</u>	Ι	Delphi Ventures VIII, L.P. (2)
Series C Preferred Stock	(1)	(1)	Common Stock	7,228	\$ <u>(1)</u>	Ι	Delphi BioInvestments VIII, L.P. (3)
Series D Preferred Stock	(1)	(1)	Common Stock	745,825	\$ <u>(1)</u>	Ι	Delphi Ventures VIII, L.P. (2)
Series D Preferred Stock	(1)	(1)	Common Stock	7,282	\$ <u>(1)</u>	Ι	Delphi BioInvestments VIII, L.P. (3)

Edgar Filing: Calithera Biosciences, Inc. - Form 3

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Delphi Management Partners VIII, L.L.C. C/O DELPHI VENTURES, 3000 SAND HILL ROAD, BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	X	Â	Â	
DELPHI VENTURES VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	X	Â	Â	
Delphi BioInvestments VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	ÂX	Â	Â	
ROEDER DOUGLAS A C/O DELPHI VENTURES	Â	ÂΧ	Â	Â	

3000 SAND HILL ROAD, BLDG. 1, SUITE 135 MENLO PARK, CA 94025	ÂX	ÂΧ	А	А
PAKIANATHAN DEEPIKA C/O DELPHI VENTURES	ÂV	ÂV	â	â
BOCHNOWSKI JAMES J C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	X	Â	Â
DOUGLASS DAVID L C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	X	Â	Â
3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CA 94025				

Signatures

By:/s/ Matthew T. Potter, Name: Matthew T. Potter, Attorney-in-Fact for:Delphi Management Partners VIII, L.L.C., Delphi Ventures VIII, L.P., Delphi BioInvestments VIII, L.P., Deepika R. Pakianathan, Douglas A. Roder, David L. Douglass and James J.Bochnowski

**Signature of Reporting Person

Date

10/01/2014

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The preferred stock is convertible at any time, at the holder's election, and has no expiration date. The preferred stock will automatically convert into common stock on a 1-to-1 basis upon closing of the initial public offering of the issuer.

The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and may be deemed to have sole voting and dispositive power over the securities held by DV

(2) VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

The reported securities are directly owned by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and may be deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J.

(3) Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.